Idec Zevalin NHL Indication Split By Accelerated/Standard Approval

Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements